Thrombophilia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
update |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{asiri}} | {{CMG}} {{AE}} {{asiri}} | ||
== | ==Overview== | ||
*It is important to determine which patients require [[Thrombophilia_screening|screening]] for thrombophilia, and subsequently which patients require [[Thrombophilia_medical_therapy|treatment]]. | *It is important to determine which patients require [[Thrombophilia_screening|screening]] for thrombophilia, and subsequently which patients require [[Thrombophilia_medical_therapy|treatment]]. | ||
*Certain [[Thrombophilia_history_and_symptoms|clinical scenarios]] may warrant [[Thrombophilia_screening|thrombophilia screening]]. | *Certain [[Thrombophilia_history_and_symptoms|clinical scenarios]] may warrant [[Thrombophilia_screening|thrombophilia screening]]. | ||
Revision as of 05:30, 16 July 2016
|
Thrombophilia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Thrombophilia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Thrombophilia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Thrombophilia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Asiri Ediriwickrema, M.D., M.H.S. [2]
Overview
- It is important to determine which patients require screening for thrombophilia, and subsequently which patients require treatment.
- Certain clinical scenarios may warrant thrombophilia screening.
- Unnecessary thrombophilia screening can lead to increased costs.